A study found that antibodies from common human coronaviruses do not cross-react with SARS-CoV-2, meaning prior infections with these viruses are unlikely to provide protection or worsen COVID-19.
Although SARS-CoV-2 (the virus that causes COVID-19) has taken the world by storm, it’s not the only coronavirus that can infect humans. But unlike SARS-CoV-2, common human coronaviruses (HCoVs) generally cause only mild disease. Now, researchers reporting in ACS Infectious Diseases have shown that infections with two different HCoVs don’t generate antibodies that effectively cross-react with SARS-CoV-2. So, prior infection with HCoVs is unlikely to protect against COVID-19 or worsen a SARS-CoV-2 infection through antibody-dependent enhancement (ADE), the researchers say.
Because SARS-CoV-2 shares significant sequence similarity with its HCoV cousins, researchers have wondered if the immune system might recognize the new coronavirus from prior bouts with HCoVs. This could re-activate memory B cells, causing them to produce antibodies that helped the person overcome previous HCoV infections, and might also help fight COVID-19. On the other hand, if the antibodies against HCoVs recognize SARS-CoV-2, but not strongly enough to generate an immune response, they could cause ADE. In this rare condition, sub-optimal antibodies actually help some viruses attach to and enter host cells, making the infection worse. Sebastien Fiedler, Tuomas Knowles and colleagues wanted to compare the strength and concentration of antibodies against HCoVs and SARS-CoV-2 in the sera of nine recovered COVID-19 patients and in three pre-pandemic sera.
The researchers used a technique called microfluidic antibody-affinity profiling, which unlike the traditionally used enzyme-linked immunosorbent assay (known as ELISA), can measure both antibody affinity and concentration independently. They found that all nine recovered COVID-19 sera samples contained moderate amounts of antibodies with high affinity to the SARS-CoV-2 spike protein. In contrast, none of the pre-pandemic sera contained high-affinity antibodies for SARS-CoV-2. All 12 sera contained low amounts of very high-affinity antibodies against two common HCoVs, indicating previous infections. Other experiments showed that these antibodies did not bind to SARS-CoV-2. The results suggest that there is no significant cross-reactivity of antibodies against common HCoVs and SARS-CoV-2, and therefore, no expected protective or adverse effects of antibody cross-reactivity for these coronaviruses, the researchers say.
Reference: “Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2” by Viola Denninger, Catherine K. Xu, Georg Meisl, Alexey S. Morgunov, Sebastian Fiedler, Alison Ilsley, Marc Emmenegger, Anisa Y. Malik, Monika A. Piziorska, Matthias M. Schneider, Sean R. A. Devenish, Vasilis Kosmoliaptsis, Adriano Aguzzi, Heike Fiegler and Tuomas P. J. Knowles, 30 March 2022, ACS Infectious Diseases.
DOI: 10.1021/acsinfecdis.1c00486
The authors acknowledge funding from the University of Zurich, the University Hospital of Zurich, the NOMIS Foundation, the European Research Council, the National Institute for Health Research, the P.I. Terasaki Scholar program, and the Biotechnology and Biological Sciences Research Council.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.